In other studies examining the comparability of different biomarkers, such as PD-L1 in non-small cell lung cancer (NSCLC), or EGFR immunohistochemistry in squamous NSCLC, significantly higher concordance between antibody clones has been observed [12,13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.